Last reviewed · How we verify
Thienopyridine
Thienopyridine is a Small molecule drug developed by Boston Scientific Corporation. It is currently in Phase 3 development. Also known as: A brand name for clopidogrel is PLAVIX., A brand name for ticlopidine is TICLID..
Thienopyridines are a class of medications used for their anti-platelet activity, specifically as selective, irreversible ADP receptor/P2Y12 inhibitors. They play a significant role in the management of cardiovascular disease, particularly in conditions such as percutaneous coronary intervention and dual anti-platelet therapy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Thienopyridine |
|---|---|
| Also known as | A brand name for clopidogrel is PLAVIX., A brand name for ticlopidine is TICLID. |
| Sponsor | Boston Scientific Corporation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thienopyridine CI brief — competitive landscape report
- Thienopyridine updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI
Frequently asked questions about Thienopyridine
What is Thienopyridine?
Who makes Thienopyridine?
Is Thienopyridine also known as anything else?
What development phase is Thienopyridine in?
Related
- Manufacturer: Boston Scientific Corporation — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: A brand name for clopidogrel is PLAVIX., A brand name for ticlopidine is TICLID.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing